tradingkey.logo

Pacira Biosciences Inc

PCRX
22.550USD
+0.360+1.62%
Horarios del mercado ETCotizaciones retrasadas 15 min
1.01BCap. mercado
PérdidaP/E TTM

Pacira Biosciences Inc

22.550
+0.360+1.62%

Más Datos de Pacira Biosciences Inc Compañía

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Información de Pacira Biosciences Inc

Símbolo de cotizaciónPCRX
Nombre de la empresaPacira Biosciences Inc
Fecha de salida a bolsaFeb 03, 2011
Director ejecutivoMr. Frank D. Lee
Número de empleados790
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 03
Dirección2000 Sierra Point Parkway
CiudadBRISBANE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94005
Teléfono16502428052
Sitio Webhttps://www.pacira.com/
Símbolo de cotizaciónPCRX
Fecha de salida a bolsaFeb 03, 2011
Director ejecutivoMr. Frank D. Lee

Ejecutivos de Pacira Biosciences Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.37K
-0.91%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Mr. Michael J. Yang
Mr. Michael J. Yang
Independent Director
Independent Director
--
--
Mr. Shawn M. Cross
Mr. Shawn M. Cross
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marcelo Bigal, M.D., Ph.D.
Dr. Marcelo Bigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Susan Mesco
Ms. Susan Mesco
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
34.37K
-0.91%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%

Desglose de ingresos

FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.89%
The Vanguard Group, Inc.
11.92%
DOMA Perpetual Capital Management, LLC
6.01%
Renaissance Technologies LLC
5.33%
D. E. Shaw & Co., L.P.
5.01%
Otro
56.84%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.89%
The Vanguard Group, Inc.
11.92%
DOMA Perpetual Capital Management, LLC
6.01%
Renaissance Technologies LLC
5.33%
D. E. Shaw & Co., L.P.
5.01%
Otro
56.84%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
51.44%
Investment Advisor/Hedge Fund
29.98%
Hedge Fund
25.77%
Research Firm
5.21%
Pension Fund
2.17%
Individual Investor
1.51%
Bank and Trust
1.03%
Holding Company
0.30%
Sovereign Wealth Fund
0.04%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
594
52.02M
115.78%
-16.12M
2025Q2
613
53.27M
118.43%
-16.03M
2025Q1
638
53.73M
116.03%
-16.46M
2024Q4
638
52.13M
112.66%
-21.91M
2024Q3
638
53.62M
116.22%
-11.06M
2024Q2
624
54.29M
116.65%
-6.10M
2024Q1
627
51.47M
110.71%
-7.99M
2023Q4
621
50.55M
108.88%
-6.71M
2023Q3
612
49.73M
107.18%
-6.05M
2023Q2
605
49.27M
107.14%
-5.45M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
6.69M
14.89%
-72.97K
-1.08%
Jun 30, 2025
The Vanguard Group, Inc.
5.36M
11.92%
+165.93K
+3.20%
Jun 30, 2025
DOMA Perpetual Capital Management, LLC
2.70M
6.01%
+894.55K
+49.59%
Aug 05, 2025
Renaissance Technologies LLC
2.40M
5.33%
--
--
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.25M
5.01%
-10.54K
-0.47%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.15M
4.79%
+102.21K
+4.99%
Jun 30, 2025
Balyasny Asset Management LP
2.13M
4.74%
+565.29K
+36.11%
Jun 30, 2025
State Street Investment Management (US)
1.95M
4.34%
-28.76K
-1.45%
Jun 30, 2025
American Century Investment Management, Inc.
1.18M
2.63%
+515.09K
+77.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.14M
2.54%
+5.66K
+0.50%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Invesco Pharmaceuticals ETF
2.69%
SPDR S&P Pharmaceuticals ETF
1.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
ETC 6 Meridian Small Cap Equity ETF
1.09%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.94%
Simplify Health Care ETF
0.92%
Invesco S&P SmallCap Health Care ETF
0.74%
VictoryShares Small Cap Free Cash Flow ETF
0.7%
Royce Quant Small-Cap Quality Value ETF
0.53%
Distillate Small/Mid Cash Flow ETF
0.48%
Ver más
Invesco Pharmaceuticals ETF
Proporción2.69%
SPDR S&P Pharmaceuticals ETF
Proporción1.8%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.35%
ETC 6 Meridian Small Cap Equity ETF
Proporción1.09%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción0.94%
Simplify Health Care ETF
Proporción0.92%
Invesco S&P SmallCap Health Care ETF
Proporción0.74%
VictoryShares Small Cap Free Cash Flow ETF
Proporción0.7%
Royce Quant Small-Cap Quality Value ETF
Proporción0.53%
Distillate Small/Mid Cash Flow ETF
Proporción0.48%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI